<DOC>
	<DOCNO>NCT02382198</DOCNO>
	<brief_summary>Sialorrhea frequently occur problem detrimental effect quality life 25 % PD patient . Currently , intervention approve sialorrhea Parkinsons evidence available 30-day effect less . We hypothesize glycopyrrolate lasting effect reduction sialorrhea PD patient .</brief_summary>
	<brief_title>Study Glycopyrrolate Moderate-to-severe Sialorrhea Parkinson 's Disease</brief_title>
	<detailed_description>To ass Glycopyrrolate long last effect sialorrhea patient Parkinsons .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Sialorrhea</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>PD define United Kingdom PD Society Brain Bank criterion Moderatetosevere sialorrhea define score item 2.2 MDSUPDRS great 2 1 . Other idiopathic parkinsonian syndrome , e.g. , Progressive Supranuclear Palsy , Corticobasal syndrome , Multiple System Atrophy 2 . Secondary parkinsonian syndrome ( druginduced , traumatic , encephalitic vascular ) 3 . Change antiparkinsonian medication one month prior enrolment 4 . Prior use glycopyrrolate without know hypersensitivity consider exclusion criterion , increase risk unblinding due prior knowledge potential side effect therapeutic benefit 5 . Change dose one month prior enrolment anticholinergic agent drug potentially affect saliva production , tricyclic antidepressant , MAOA inhibitor , neuroleptic ( include clozapine quetiapine frequently use PD ) hypnotic . These medication remain constant dose throughout trial ; 6 . Concomitant use solid oral dosage form potassium chloride ; 7 . Pregnancy , breastfeeding , premenopausal female male use adequate contraception ; medically acceptable birth control method study include : ( 1 ) Abstinence ( sexual intercourse ) ; ( 2 ) Intrauterine device ( IUD ) ; ( 3 ) Diaphragm spermicide ; ( 4 ) Condom spermicide ; ( 5 ) Oral contraceptive ( birth control pill ) + condom/diaphragm spermicide . 8 . Moderatetosevere constipation spite optimal treatment ( MDSUPDRS , item 1.11 &gt; 2 ) ; 9 . Conditions preclude anticholinergic therapy , e.g. , document history symptom suggestive inflammatory bowel disease , glaucoma , myasthenia gravis , prostatic hypertrophy obstructive urinary symptom ; 10 . Conditions exacerbate anticholinergic effect glycopyrrolate , e.g. , document history symptom suggestive congestive heart failure , coronary heart disease , gastroesophageal reflux disease hyperthyroidism ; 11 . Uncontrolled arterial hypertension ( TAS &gt; 140 mmHg TAD &gt; 90 mmHg , use electronic sphygmomanometer standardize procedure16 ) ; 12 . Tachyarrhythmia ( interval RR &lt; 0.6 sec . ) ; 13 . TSH &lt; 0.4 mIU/L ; 14 . Liver dysfunction ( AST , ALT , ALP &gt; 2xUpper Normal Limit ) ; 15 . Renal dysfunction ( creatinine clearance &lt; 50 mL/min ) , glycopyrrolate predominant renal clearance ; 16 . Inability unwillingness subject legal guardian/representative give write informed consent ; 17 . Clinical significant lactose intolerance know hypersensitivity study medication excipients 18 . Participation another investigational study time recruitment prior month .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>droooling , sialorrhea , parkinson 's disease , parkinson</keyword>
</DOC>